ClinConnect ClinConnect Logo
Search / Trial NCT06894719

Oral Tranexamic Acid After Total Knee Arthroplasty

Launched by RUSH UNIVERSITY MEDICAL CENTER · Mar 18, 2025

Trial Information

Current as of April 29, 2025

Not yet recruiting

Keywords

Tranexamic Acid Range Of Motion Postoperative Pain Postoperative Function

ClinConnect Summary

This clinical trial is looking at how effective a medication called oral tranexamic acid (TXA) is for patients who have undergone total knee arthroplasty (TKA), which is a surgery to replace the knee joint. The study will compare patients who take TXA for either 3 or 7 days after their surgery with those who do not take the medication. Researchers want to find out if TXA helps reduce pain and improve how well patients can move their knee in the first few months after surgery, while also checking if there is any difference in blood loss and the need for blood transfusions.

To be eligible for this trial, participants must be adults aged 65 to 74 who are scheduled for a total knee replacement at a specific hospital. They should be willing to take a chance on whether they receive the medication or not and answer daily questions about their pain levels and how well they are getting around. However, certain individuals, such as those with a recent history of blood clots, heart attacks, strokes, or those taking specific medications, may not qualify. Participants can expect to be part of a study that aims to improve pain management and recovery outcomes for future knee surgery patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Any patient undergoing primary TKA at Rush main hospital or participating ASC
  • Willingness to undergo randomization to take medication potentially up to 7 days post op.
  • Willing to answer daily questions on pain, functionality and opioid consumption
  • Exclusion Criteria:
  • History of venous thromboembolism, MI, or stroke in the past year
  • Patients on any chronic anticoagulation medications besides Aspirin
  • Patients with Cancer
  • Patients with end stage renal disease that are on dialysis
  • Drug allergy to TXA
  • Taking oral birth control
  • Unable to provide consent

About Rush University Medical Center

Rush University Medical Center is a leading academic medical institution located in Chicago, Illinois, dedicated to advancing healthcare through innovative research and clinical trials. As a sponsor of numerous clinical studies, Rush focuses on translating scientific discoveries into effective treatments and improving patient outcomes across a variety of medical disciplines. With a commitment to excellence in patient care, education, and research, Rush leverages its state-of-the-art facilities and a robust network of specialists to conduct comprehensive trials that adhere to the highest ethical and regulatory standards. Through collaboration with a diverse patient population, Rush aims to enhance the understanding of diseases and develop novel therapeutic strategies.

Locations

Patients applied

0 patients applied

Trial Officials

Bailey Terhune, MD

Principal Investigator

Rush University Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported